Recombinant ZIKV E anticorps

N° du produit ABIN6253501

Cet anticorps anti-ZIKV E est un anticorps Human Monoclonal détectant ZIKV E dans Func. Adapté pour Zika Virus (ZIKV).

Aperçu rapide pour Recombinant ZIKV E anticorps (ABIN6253501)

Antigène: ZIKV E (Zika Virus Envelope (ZIKV E))

Type d'anticorp: Recombinant Antibody

Reactivité: Zika Virus (ZIKV)

Hôte: Human

Clonalité: Monoclonal

Conjugué: Cet anticorp ZIKV E est non-conjugé

Application: Functional Studies (Func)

Clone: ZKA64

Détail du produit anti-ZIKV E anticorps

Fonction: anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free)

Attributs du produit: Recombinant Antibody. Recognizes and binds specifically to the EDIII domain of the Zika Virus envelope protein (ZIKV E). It does not cross-react with Dengue virus envelope protein (DENV E). Species cross-reactivity: Virus. Clone: ZKA64. Isotype: Human IgG1kappa. Applications: FUNC, FUNC (Blocking). Host: . Liquid. In PBS. The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.

Pureté: >95 % (SDS-PAGE)

niveau d'endotoxine: <0.001EU/μg

Immunogène: Zika Virus

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: Lot specific

Buffer: Liquid. In PBS.

Agent conservateur: Without preservative

Conseil sur la manipulation: Avoid freeze/thaw cycles.

Stock: 4 °C,-20 °C

Stockage commentaire:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.

Détails sur ZIKV E

Antigène: ZIKV E (Zika Virus Envelope (ZIKV E))

Autre désignation: Zika Virus Envelope Protein

Classe de substances: Viral Protein

Sujet:

Alternate Names/Synonyms: ZIKV E Protein

Product Description: The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.